Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 4,767 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Branch II Clear all

Conditions: Lung Neoplasm
Interventions: Computed Tomography, Diagnostic Procedure, Best Practice, Electronic Health Record Review; Procedure · Device · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 35 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Aurora, Colorado • St Louis, Missouri • Nashville, Tennessee

Conditions: HIV Infections, AIDS
Interventions: efavirenz, stavudine extended release, lamivudine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 10
States / cities: Bakersfield, California • San Francisco, California • Washington D.C., District of Columbia + 7 more

Conditions: Uveal Melanoma
Interventions: Stereotactic Body Radiation Therapy, Ziv-Aflibercept; Radiation · Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Castrate Resistant Prostate Cancer
Interventions: Ipatasertib, Darolutamide, Androgen Deprivation Therapy; Drug
Lead sponsor: David VanderWeele; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Chicago, Illinois • Indianapolis, Indiana • Hershey, Pennsylvania

Conditions: Non-Hodgkin Lymphoma, Follicular Lymphoma
Interventions: 10 MBq/kg Betalutin, 15 MBq/kg Betalutin, 20 MBq/kg Betalutin, 40 mg lilotomab, 100 mg/m2 lilotomab, 60 mg/m2 lilotomab, Rituximab, 12.5 mBq/kg Betalutin; Drug
Lead sponsor: Nordic Nanovector; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 14
States / cities: Little Rock, Arkansas • Long Beach, California • San Francisco, California + 10 more

Conditions: ARDS, Human, Lung, Wet, Thyroid, Pulmonary Edema, Lung Inflammation
Interventions: Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation., Non-intervention; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Edina, Minnesota • Minneapolis, Minnesota

Conditions: SARS-CoV 2
Interventions: Phase 1, Phase 2; Radiation
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Peripheral Neuropathy
Interventions: venlafaxine, placebo, questionnaire administration, quality-of-life assessment; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
Interventions: alvocidib, mitoxantrone hydrochloride, carboplatin, cytarabine, sirolimus, etoposide, topotecan hydrochloride; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 19
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 15 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis
Interventions: Tozorakimab, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 16
States / cities: Sheffield, Alabama • Newport Beach, California • Newark, Delaware + 13 more

Conditions: Follicular Lymphoma
Interventions: Bendamustine, Rituximab, Tazemetostat; Drug
Lead sponsor: Vaishalee Kenkre; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Chicago, Illinois • New Brunswick, New Jersey • Columbus, Ohio + 1 more

Conditions: Hematopoietic Neoplasm
Interventions: SAR302503; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 16
States / cities: Phoenix, Arizona • San Francisco, California • Atlanta, Georgia + 10 more

Conditions: Ulcerative Colitis
Interventions: UTTR1147A, UTTR1147A Placebo, Vedolizumab, Vedolizumab Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Greenville, North Carolina • Salt Lake City, Utah

Conditions: Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Non-Small Cell Lung Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Squamous Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
Interventions: Radiation Therapy, Carboplatin, Metformin, Paclitaxel; Radiation · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 219
States / cities: Tuscaloosa, Alabama • Tucson, Arizona • Auburn, California + 176 more

Conditions: Pain Management
Interventions: Interactive DVD, Usual Care; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pancreas Cancer
Interventions: TG01 Vaccine, QS-21, Balstilimab; Biological · Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 5
States / cities: Fairway, Kansas • Overland Park, Kansas • Westwood, Kansas + 2 more

Conditions: Influenza,Human, COVID-19
Interventions: Investigational Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza/COVID-19 Vaccine, Licensed Influenza Vaccine 1, Licensed Influenza Vaccine 2, Placebo; Biological · Combination Product · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 1,353 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 22
States / cities: Lake Forest, California • San Diego, California • Walnut Creek, California + 17 more

Conditions: Atypical Ductal Breast Hyperplasia, Atypical Lobular Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Interventions: counseling intervention, behavioral dietary intervention, exercise intervention, questionnaire administration, laboratory biomarker analysis; Other · Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 35 Years to 65 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: celecoxib, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Intraductal arm, Intravenous arm; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 2
States / cities: Indianapolis, Indiana • Baltimore, Maryland

Conditions: Adult Liposarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions: nelfinavir mesylate, biopsy, laboratory biomarker analysis, pharmacological study, gene expression analysis, western blotting, reverse transcriptase-polymerase chain reaction, immunoenzyme technique; Drug · Procedure · Other + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 2
States / cities: Duarte, California • Pasadena, California

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Cancer, Functional Limitation
Interventions: Functional Resistance Training, Stretching, Delayed Functional Resistance Training; Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 65 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Low Back Pain, Chronic Pain
Interventions: Physical Therapy, Cognitive Behavioral Therapy, Mindfulness, Phase I Treatment, Phase II Switching; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 64 Years
Enrollment: 749 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Baltimore, Maryland • Salt Lake City, Utah

Conditions: Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma
Interventions: AL3818, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Carboplatin; Drug
Lead sponsor: Advenchen Laboratories, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 8
States / cities: Long Beach, California • Miami, Florida • Lexington, Kentucky + 5 more

Search by objective public record fields.

Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules

DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy

Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma

Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer

A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma

Treatment of ARDS With Instilled T3

Lung Irradiation for COVID-19 Pneumonia

Venlafaxine in Preventing Chronic Oxaliplatin-Induced Neuropathy In Patients Receiving Combination Chemotherapy

Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)

Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

The Alabama NSAIDs Patient Safety Survey, Phase II: Reducing Disparities in Risk Awareness and Communication

Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer

A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People

Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer

Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer

Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer

Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma

Phase I Randomized Controlled Trial of Functional Resistance Training in Older Cancer Survivors: The ACES Trial

Optimize Low Back Pain

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)